Author:
Pavlovsky Carolina,Vasconcelos Cordoba Bianca,Sanchez María Belén,Moiraghi Beatriz,Varela Ana,Custidiano Rosario,Fernandez Isolda,Freitas Maria Josefina,Ventriglia Maria Verónica,Bendek Georgina,Mariano Romina,Mela Osorio María José,Pavlovsky Miguel Angel,de Labanca Ana García,Foncuberta Cecilia,Giere Isabel,Vera Masiel,Juni Mariana,Mordoh Jose,Sanchez Avalos Julio Cesar,Cueto Gerardo,Miranda Silvia,Levy Estrella Mariel,Bianchini Michele
Abstract
AbstractTreatment-free remission (TFR) in chronic myeloid leukemia (CML) is safe under adequate molecular monitoring, but questions remain regarding which factors may be considered predictive for TFR. Argentina Stop Trial (AST) is a multicenter TFR trial showing that 65% of patients sustain molecular remission, and the prior time in deep molecular response (DMR) was associated with successful TFR. Luminex technology was used to characterize cytokines in plasma samples. Using machine learning algorithms, MCP-1 and IL-6 were identified as novel biomarkers and MCP-1low/IL-6low patients showed eightfold higher risk of relapse. These findings support the feasibility of TFR for patients in DMR and MCP-1/IL-6 plasma levels are strong predictive biomarkers.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Molecular Biology,Hematology